| Jul 17 |
Royalty Pharma Declares Third Quarter 2024 Dividend
|
| Jul 2 |
Is Royalty Pharma plc (RPRX) a Good Stock to Buy Now?
|
| Jun 22 |
Royalty Pharma plc (NASDAQ:RPRX) is largely controlled by institutional shareholders who own 70% of the company
|
| Jun 4 |
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
|
| Jun 3 |
Royalty Pharma announces pricing of $1.5B of senior unsecured notes
|
| May 28 |
Agios in pact with Royalty Pharma for brain tumor candidate
|
| May 28 |
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
|
| May 22 |
Cytokinetics to get up to $575M in funding from Royalty Pharma
|
| May 22 |
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
|
| May 22 |
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
|
